

5. To provide scientific, regulatory and legal expertise at the request of national, European and international bodies.

The generic industry is requested to provide expert opinion and knowledge during the establishment of national, European and international regulatory guidelines and legal instruments. The EGA will co-ordinate and facilitate the input of experts from national companies and associations to these bodies.

6. To represent the common interests of its members at EU level as well as seeking measures that will ensure access to affordable medicines for patients in Europe.

The EGA assists its members in influencing the decision-making process at EU level. For this purpose the EGA maintains and develops relations with the European Commission, the European Parliament and member state representatives. The EGA has a representation office in the heart of the European quarter in Brussels - only minutes walk from the European Parliament and main offices of the European Commission. The EGA is also considering opening in the future an office in London to facilitate member's activities with the EMEA.

## MEMBERSHIP OF THE EGA

The EGA has members from throughout Europe - not only the EU. Membership of the EGA is open to pharmaceutical companies and associations, which meet the following criteria:

- Being commercially active in Europe;
- Meet all the obligations of EGA membership;
- Demonstrate that their activities are in accordance with the objectives of the Association;
- Demonstrate that their activities are not in conflict with promoting the interests of the European generic pharmaceutical and bulk chemical industries.

Most companies and associations join as **Ordinary Members** (i.e. Full Members) and enjoy the benefits of all the activities of the EGA listed above. However, **Associate Membership** is open to those: a) who wish only to enjoy limited benefits of membership (i.e. access to the *EGA-EU Brief* and preferential access for public events) or those: b) whose activities the EGA Board of Directors deem not to be directly related to the interests of the Association.

EGA

P.O. Box 193 - B-1040 Brussels  
Tel. +32 (02) 736 84 11 - Fax +32 (02) 736 74 38  
[www.egagenerics.com](http://www.egagenerics.com)

For further information on the EGA  
or on how to join the Association please contact:  
[info@egagenerics.com](mailto:info@egagenerics.com)



*Making Medicines Affordable*


EUROPEAN GENERIC MEDICINES ASSOCIATION




*Making Medicines Affordable*

## EUROPEAN GENERIC MEDICINES ASSOCIATION

### ACTIVITIÉS & MEMBERSHIP



[www.egagenerics.com](http://www.egagenerics.com)



## THE EGA'S STATUS AND OBJECTIVES

The EGA was established in 1993. The Association is established as an international non-profit making organisation (ASBL) under Belgian law. Its objectives, composition and internal working procedures are governed by its Statutes of Association and Rules of Procedure. The primary objective of the Association is:

*To represent, support and develop the common scientific and technical interest of the European generic pharmaceutical industry and bulk chemical producers or national or European associations of such persons, firms, companies or other legal bodies active in the generic pharmaceutical or bulk chemical producers industries (Article 3 Statutes of Association).*

Although formally based in Brussels, the EGA and its experts carry out activities throughout Europe in conjunction with the Association's member companies and associations.

## SIX MAIN ACTIVITIES OF THE EGA

The activities of the Association fall in to six main areas:

**1. To monitor, study and analyse those scientific, legal and technical developments at European and international level that impact upon the common interests of its membership.**


To facilitate this activity the EGA has established four committees - *The Regulatory and Scientific Affairs Committee, the Legal Affairs and Intellectual Property Committee, the Health Economics Committee, the Biotechnology Committee and the EU Accession Committee.* The EGA also creates ad hoc working groups to follow specific issues or developments, such as the *Bio-generic Working Group.* These committees and working groups meet throughout the year in various locations around Europe.

**2. To inform its members of trends, developments and implications of any scientific, legal and technical issues impacting on the generic pharmaceutical industry.**

As part of this activity EGA members receive a regular 20-30 page *EGA-EU Brief*, covering legislative, regulatory, scientific, intellectual property, international and EU enlargement issues. Produced by legal, regulatory and policy experts in the EU and pharmaceuticals fields, the *EGA-EU Brief* provides a unique and up-to-date source of information to its members. The *EGA-EU Brief* is sent to EGA members in electronic format and is complete with links to relevant websites in case more detailed information is required. In addition members also receive *EGA Briefing Notes* on various policy developments, proposed laws and guidelines.

**3. To provide educational and technical assistance to its members and the general public.**

As part of this activity the EGA holds regular conferences, seminars, and workshops for its members. Some of these events, such as the *EGA's Annual Conference* are also open to the general public, although EGA members are entitled to preferential prices. In addition, the EGA is also a



Folic acid through microscope under polarized light

co-organiser of the annual International Generic Pharmaceutical Alliance (IGPA) conference and IGPA mid term Intellectual Property and scientific workshops. Information is also made available to the general public through the EGA's website [www.egagenetics.com](http://www.egagenetics.com).

**4. To provide a network of information, co-operation and assistance with other generic pharmaceutical associations at national, regional and international level.**

The EGA places as a priority the encouragement of the formation of generic pharmaceutical and bulk chemical associations in European countries where they do not exist. An *EGA National Co-ordinators Group* has also been established to facilitate the network of scientific, regulatory and legal information as well mutual assistance between the various generic national associations and companies in Europe. The EGA is a founding member of the International Generic Pharmaceutical Alliance (IGPA) and a member of its Management Board. The IGPA was established in 1998, principally as a network for information and advice between generic associations in Canada, the EU, India and the USA.

EUROPEAN GENERIC  
MEDICINES ASSOCIATION